Cargando…

OA01.03 Immune Checkpoint Inhibitor Dose Adaptation During the COVID-19 Pandemic in Non-Small Cell Lung Cancer– a Single-Center Experience

Detalles Bibliográficos
Autores principales: Hijmering-Kappelle, L., Hiltermann, T.j.n., Bensch, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523140/
http://dx.doi.org/10.1016/j.jtho.2021.08.036
_version_ 1784585235191562240
author Hijmering-Kappelle, L.
Hiltermann, T.j.n.
Bensch, F.
author_facet Hijmering-Kappelle, L.
Hiltermann, T.j.n.
Bensch, F.
author_sort Hijmering-Kappelle, L.
collection PubMed
description
format Online
Article
Text
id pubmed-8523140
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-85231402021-10-20 OA01.03 Immune Checkpoint Inhibitor Dose Adaptation During the COVID-19 Pandemic in Non-Small Cell Lung Cancer– a Single-Center Experience Hijmering-Kappelle, L. Hiltermann, T.j.n. Bensch, F. J Thorac Oncol Oa01 the Impact of Covid-19 on Patients with Lung Cancer Wednesday, September 08, 2021 - 08:15-09:15 Published by Elsevier Inc. 2021-10 2021-10-18 /pmc/articles/PMC8523140/ http://dx.doi.org/10.1016/j.jtho.2021.08.036 Text en Copyright © 2021 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Oa01 the Impact of Covid-19 on Patients with Lung Cancer Wednesday, September 08, 2021 - 08:15-09:15
Hijmering-Kappelle, L.
Hiltermann, T.j.n.
Bensch, F.
OA01.03 Immune Checkpoint Inhibitor Dose Adaptation During the COVID-19 Pandemic in Non-Small Cell Lung Cancer– a Single-Center Experience
title OA01.03 Immune Checkpoint Inhibitor Dose Adaptation During the COVID-19 Pandemic in Non-Small Cell Lung Cancer– a Single-Center Experience
title_full OA01.03 Immune Checkpoint Inhibitor Dose Adaptation During the COVID-19 Pandemic in Non-Small Cell Lung Cancer– a Single-Center Experience
title_fullStr OA01.03 Immune Checkpoint Inhibitor Dose Adaptation During the COVID-19 Pandemic in Non-Small Cell Lung Cancer– a Single-Center Experience
title_full_unstemmed OA01.03 Immune Checkpoint Inhibitor Dose Adaptation During the COVID-19 Pandemic in Non-Small Cell Lung Cancer– a Single-Center Experience
title_short OA01.03 Immune Checkpoint Inhibitor Dose Adaptation During the COVID-19 Pandemic in Non-Small Cell Lung Cancer– a Single-Center Experience
title_sort oa01.03 immune checkpoint inhibitor dose adaptation during the covid-19 pandemic in non-small cell lung cancer– a single-center experience
topic Oa01 the Impact of Covid-19 on Patients with Lung Cancer Wednesday, September 08, 2021 - 08:15-09:15
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523140/
http://dx.doi.org/10.1016/j.jtho.2021.08.036
work_keys_str_mv AT hijmeringkappellel oa0103immunecheckpointinhibitordoseadaptationduringthecovid19pandemicinnonsmallcelllungcancerasinglecenterexperience
AT hiltermanntjn oa0103immunecheckpointinhibitordoseadaptationduringthecovid19pandemicinnonsmallcelllungcancerasinglecenterexperience
AT benschf oa0103immunecheckpointinhibitordoseadaptationduringthecovid19pandemicinnonsmallcelllungcancerasinglecenterexperience